Skip to content
StockMarketAgent
Sector pending / Medical LaboratoriesUpdated 2026-05-10 22:07 UTC

FRA/NG9 stock hub

FRA/NG9 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

FRA/NG9is not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
991.2M
Frankfurt Stock Exchange
Market data

Price

Recent price action with selectable time range.

FRA/NG9FRA/NG9
—
Loading chart…
In the news

Latest news · FRA/NG9

Recent company headlines from major financial publishers.

Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E36
P25 n/aP50 n/aP75 n/a
Trailing P/En/a
P25 n/aP50 n/aP75 n/a
ROE-11.6
P25 n/aP50 n/aP75 n/a
ROIC-5.7
P25 n/aP50 n/aP75 n/a
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All FRA/NG9 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
181
Groups with data
11
Currency
USD
Showing 181 of 181 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

18
MetricValue
Country
United States
Country code
DE
Employees
2,500
Employees Change
100%
Employees Change Percent
4.76
Enterprise value
EUR 1.2B
Exchange
Frankfurt Stock Exchange
Financial currency
USD
First seen
2026-05-10
Industry
Medical Laboratories
Last refreshed
2026-05-10
Market cap
EUR 991.2M
Price
EUR 7.64
Price currency
EUR
Rev Per Employee
258,791.57x
Sic
8071
Symbol
fra/NG9
Website
https://www.neogenomics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

9
MetricValue
Earnings Yield
-8.68%
EV Earnings
-14.11x
EV/EBITDA
107.67x
EV/FCF
-275.14x
EV/Sales
1.92x
FCF yield
-0.45%
Forward P/E
35.96x
P/B ratio
1.38x
P/S ratio
1.53x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

19
MetricValue
EBIT Margin
-8.34%
EBITDA Margin
0.57%
Gross margin
43.1%
Gross Profit
EUR 278.8M
Gross Profit Growth
7.93%
Gross Profit Growth Q
10.4%
Gross Profit Growth3 Y
16.28%
Gross Profit Growth5 Y
11.52%
Net Income
EUR -86M
Pretax Margin
-13.7%
Profit Margin
-13.3%
Profit Per Employee
EUR -34,417
ROA
-2.64
Roa5y
-3.92
ROCE
-4.93
ROE
-11.56
Roe5y
-8.93
ROIC
-5.72
Roic5y
-9.38

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

11
MetricValue
Cagr10y
1.2%
Cagr1y
10.7%
Cagr3y
-16.45%
Cagr5y
-26.18%
OCF Growth
194.57%
OCF Growth10 Y
4.64%
OCF Growth5 Y
16.16%
Revenue Growth
10.95x
Revenue Growth Q
11.09x
Revenue Growth3 Y
12.08x
Revenue Growth5 Y
10.44x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

20
MetricValue
Asset Turnover
EUR 0.51
Assets
EUR 1.2B
Cash
EUR 126.7M
Current Assets
EUR 316.9M
Current Liabilities
EUR 71.7M
Debt
EUR 354.3M
Debt EBITDA
EUR 30.78
Debt Equity
EUR 0.49
Debt FCF
EUR -80.29
Equity
EUR 718.8M
Interest Coverage
-22.77
Liabilities
EUR 449.1M
Long Term Assets
EUR 851M
Long Term Liabilities
EUR 377.3M
Net Cash
EUR -227.6M
Net Cash By Market Cap
EUR -22.96
Net Debt EBITDA
EUR 61.49
Net Debt Equity
EUR 0.32
Tangible Book Value
EUR 22.4M
Tangible Book Value Per Share
EUR 0.17

Liquidity

Current-asset coverage and working-capital efficiency metrics.

6
MetricValue
Current ratio
4.42
Inventory Turnover
14.24
Net Working Capital
EUR 128.2M
Quick ratio
3.71
Working Capital
EUR 250.7M
Working Capital Turnover
EUR 2.22

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

1
MetricValue
Buyback Yield
-1.24%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

35
MetricValue
10Y total return
12.71%
1Y total return
10.7%
200-day SMA
8.01
3Y total return
-41.69%
50-day SMA
7.17
50-day SMA vs 200-day SMA
50under200
5Y total return
-78.07%
All Time High
49.8
All Time High Change
-84.66%
All Time High Date
2021-02-16
All Time Low
2.15
All Time Low Change
255.75%
All Time Low Date
2014-05-09
ATR
0.19
Ch YTD
-26.56
High
7.64
High52
11.3
High52 Date
2026-01-15
High52ch
-32.41%
Low
7.64
Low52
4.2
Low52 Date
2025-08-01
Low52ch
81.86%
Ma50ch
6.47%
Price vs 200-day SMA
-4.68%
RSI
57.68
RSI Monthly
43.65
RSI Weekly
46.35
Sharpe ratio
0.33x
Sortino ratio
0.58
Total Return
-1.24%
Tr YTD
-26.56
Tr1m
11.21%
Tr1w
-3.66%
Tr3m
-17.87%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

2
MetricValue
Operating Income
EUR -54M
Operating margin
-8.34

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

7
MetricValue
Float
118,894,953%
Net Borrowing
-170,652,352.5
Shares Insiders
1.95%
Shares Institutions
107.33%
Shares Qo Q
0.4%
Shares Yo Y
1.24%
Short Ratio
3.71

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

53
MetricValue
Adjusted FCF
EUR -39.3M
Average Volume
172.5x
Bv Per Share
5.54
CAPEX
EUR -23.9M
Ch10y
12.71
Ch1m
11.21
Ch1w
-3.66
Ch1y
10.7
Ch3m
-17.87
Ch3y
-41.69
Ch5y
-78.07
Ch6m
-14.66
Change
1.87%
Change From Open
-0.03
Close
7.5
Days Gap
1.87
Depreciation Amortization
56,397,104.7
Earnings Date
2026-04-28
EBIT
EUR -54M
EBITDA
EUR 3.7M
EPS
EUR -0.67
F Score
4
FCF
EUR -4.4M
FCF EV Yield
-0.36x
Financing CF
-174,825,998
Fiscal Year End
December
Founded
2,001
Goodwill
444,327,848.2
Income Tax
EUR -2.6M
Investing CF
-18,123,101
Is Primary Listing
0
Last Earnings Date
2026-04-28
Last Report Date
2026-03-31
Ma150
8.71
Ma150ch
-12.3%
Ma20
7.14
Ma20ch
6.97%
Net CF
-173,504,232
Next Earnings Date
2026-07-29
Open
7.64
P OCF Ratio
50.98
Ppne
135,980,882.2
Price Date
2026-05-08
Price EBITDA
EUR 268
Ptbv Ratio
44.18
Relative Volume
20x
Revenue
646,978,914x
SBC By Revenue
5.39x
Share Based Comp
34,863,725
Tax By Revenue
-0.4x
Tr6m
-14.66%
Volume
0
Z Score
1.55
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does FRA/NG9 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/NG9 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+10.7%
S&P 500 1Y: n/a
3Y total return
-41.7%
S&P 500 3Y: n/a
5Y total return
-78.1%
S&P 500 5Y: n/a
10Y total return
+12.7%
S&P 500 10Y: n/a
Ownership

Who owns FRA/NG9?

Insider, institutional, and short-interest positioning.

Institutional ownership
+107.3%
Share of float held by funds and institutions
Insider ownership
+2.0%
Stake held by company insiders. Higher generally signals alignment.
Short interest
n/a
3.7 days to cover
Y/Y dilution
+1.2%
Negative means the company is buying back shares.
Technical

FRA/NG9 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
57.7
Neutral momentum band
Price vs 200-day MA
-4.7%
50/200-day relationship not available
Beta (5Y)
n/a
Sensitivity to the broader market
Sharpe ratio
0.33
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About FRA/NG9

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/NG9 stock rating?

fra/NG9 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/NG9 analysis?

The full report lives at /stocks/fra/NG9/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/NG9?

The latest report frames fra/NG9 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/NG9 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.